https://novaprd-lb.newcastle.edu.au/vital/access/manager/Index ${session.getAttribute("locale")} 5 Knowledge of risk management strategies, and information and risk management preferences of women at increased risk for ovarian cancer https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:526 Thu 25 Jul 2013 09:10:32 AEST ]]> Early stopping of clinical trials (Commentary) https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:165 Thu 25 Jul 2013 09:09:46 AEST ]]> CDKN2A common variants and their association with melanoma risk: A population-based study https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:154 g and Nt540c>t, which have been detected in other populations. To establish if they are associated with an increased malignant melanoma (MM) risk we did an association study based on genotyping 471 patients with MM and 1,2 10 random control subjects from the same Polish population. We found a significantly increased frequency of the A148T variant among patients with MM (7.0%) in comparison with the general population (2.9%). The incidence of the A148T variant remained greater in both unselected and familial melanoma subgroups. A statistically significant positive association was seen for unselected MM (odds ratio, 2.529; P = 0.0003), especially in patients diagnosed under 50 years of age (odds ratio, 3.4; P = 0.0002). The A148T carrier population (heterozygous G/A alleles) was more likely to have a relative with malignancy compared with the noncarrier population (57% versus 36%, respectively; P = 0.03). Further examination of the CDKN2A promoter sequence done in 20 melanoma patients with the A148T change (heterozygous G/A alleles) and 20 patients with MM without this alteration identified it was in linkage disequilibrium with a polymorphism in the promoter region at position P-493. We found no statistically significant overrepresentation of the Nt500c>g and the Nt540c>t polymorphisms in the Polish melanoma population. In conclusion, the A148T variant of the CDKN2A gene seems to be associated with an increased risk of development of MM. Additional studies are required to confirm whether this particular change is associated with increased risk of other nonmelanoma malignancies.]]> Thu 25 Jul 2013 09:09:40 AEST ]]> Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:14877 Sat 24 Mar 2018 08:22:24 AEDT ]]> The use of complementary and alternative therapies by patients with cancer https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:236 Sat 24 Mar 2018 07:42:43 AEDT ]]> Folic acid: vitamin and panacea or genetic time bomb? https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:357 Sat 24 Mar 2018 07:42:37 AEDT ]]> Naturopathy/herbalism consultations by mid-aged Australian women who have cancer https://novaprd-lb.newcastle.edu.au/vital/access/manager/Repository/uon:55 Sat 24 Mar 2018 07:42:00 AEDT ]]>